Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
88.19
+0.96 (+1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Via
InvestorPlace
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday
January 23, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Key Takeaways From BioNTech Analyst Ratings
January 23, 2024
Via
Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
January 17, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
P/E Ratio Insights for BioNTech
January 09, 2024
Via
Benzinga
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
January 03, 2024
Via
Benzinga
BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025
January 09, 2024
On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P.
Via
Benzinga
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
5 Value Stocks To Watch In The Healthcare Sector
January 01, 2024
Via
Benzinga
How Is The Market Feeling About BioNTech?
December 26, 2023
Via
Benzinga
Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors
December 20, 2023
Via
Benzinga
What's Going On With BioNTech (BNTX) Shares?
December 13, 2023
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading lower by 5.6% to $93.10 Wednesday afternoon.
Via
Benzinga
6 Analysts Have This to Say About BioNTech
December 01, 2023
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
December 25, 2023
Via
Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n
Via
Benzinga
Exposures
COVID-19
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
December 19, 2023
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
December 18, 2023
Analysts think these beaten-down stocks could rebound strongly in the new year.
Via
The Motley Fool
Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday
December 13, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sharply during Wednesday’s session after the company...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
December 13, 2023
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target.
Via
Investor's Business Daily
What's Going On With Moderna Stock Today?
December 12, 2023
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and
Via
Benzinga
BioNTech Stock Downgraded, Analyst Reflects Concerns Over Growth and Pipeline Development
December 01, 2023
J.P.
Via
Benzinga
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
December 01, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Dell Reports Mixed Q3 Results, Joins Marvell Technology, Super Micro Computer And Other Big Stocks Moving Lower In Friday's Pre-Market Session
December 01, 2023
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining more than 80 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is COVID-19 Vaccine Maker Moderna Stock Trading Lower Today?
November 21, 2023
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc (NYSE: PFE) /
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
November 15, 2023
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
3 Biotech Stocks You’ll Regret Not Buying Soon: November 2023
November 14, 2023
The global biotechnology market could nearly triple by 2030. Investors should consider buying these biotech stocks before they explode.
Via
InvestorPlace
Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
November 14, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.